Global Biosimilar Interleukins Market Trends And Strategies Of Major Players In The Biosimilar Interleukins Market 2021-2030
2 Dec, 2021
Check out TBRC’s sale today for The biosimilar interleukins market consists of sales of interleukin biosimilars generated by the establishments that manufacture interleukin biosimilars that are used to treat various autoimmune diseases. Interleukin is a substance derived from white blood cells that enhances infection activity and is used to fight certain types of cancer.
The biosimilar interleukins market consists of sales of interleukin biosimilars generated by the establishments that manufacture interleukin biosimilars that are used to treat various autoimmune diseases. Interleukin is a substance derived from white blood cells that enhances infection activity and is used to fight certain types of cancer.
Global Biosimilar Interleukins Market Size And Drivers:
The global biosimilar interleukins market is expected to grow from $1.03 billion in 2020 to $1.33 billion in 2021 at a compound annual growth rate (CAGR) of 29.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar interleukins market is expected to reach $4.94 billion in 2025 at a CAGR of 39%. The increasing prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market in the forecast period.
Request For A Sample For The Global Biosimilar Interleukins Market Report:
Trends In The Global Biosimilar Interleukins Market
In January 2020, Sanofi, a France-based pharmaceutical company, acquired Synthorx, Inc. for $2.5 billion. This acquisition enhances Sanofi’s position as an emerging leader in the area of oncology and immunology. Synthorx, Inc. is a US-based biotechnology company focused on developing interleukins for people suffering from cancer and autoimmune disorders.
Global Biosimilar Interleukins Market Segments:
The global biosimilar interleukins market is further segmented –
By Type: IL-17, IL-23, IL-1, IL-5, IL-6
By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Others
By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes
By Geography: The global biosimilar interleukins market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.
Read More On The Report For The Global Biosimilar Interleukins Market At:https://www.thebusinessresearchcompany.com/report/biosimilar-interleukins-global-market-report-2020-30-covid-19-growth-and-change
Biosimilar Interleukins Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides biosimilar interleukins market overviews, analyzes and forecasts market size and growth for the global biosimilar interleukins market, biosimilar interleukins market share, biosimilar interleukins market players, biosimilar interleukins market segments and geographies, biosimilar interleukins market’s leading competitors’ revenues, profiles and market shares. The biosimilar interleukins market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.